The FDA handed out a string of approvals in late February and early March, granting regulatory clearances across several therapeutic areas - from oncology and rare genetic disorders to growth deficiencies.Let's take a look at the treatments that recently secured the regulatory nod.Boehringer Ingelheim Pharmaceuticals Inc. On February 26, 2026, the FDA granted accelerated approval to Boehringer Ingelheim's Hernexeos as a first-line treatment for adult patients with advanced non-small cell lung cancer (NSCLC ...

Core Viewpoint - Johnson & Johnson units have agreed to pay $65 million to settle an antitrust class action lawsuit regarding the pulmonary hypertension drug Tracleer, which alleged overcharging and delayed competition for a generic version of the drug [1]. Group 1: Settlement Details - The preliminary settlement was filed in federal court in Maryland and requires judicial approval [1]. - The settlement covers Tracleer purchases in 31 states, the District of Columbia, and Puerto Rico from December 2015 to September 2024 [1]. - Plaintiffs plan to seek approximately 33% of the settlement fund for legal fees, amounting to about $21 million [1]. Group 2: Allegations and Background - The lawsuit, initiated in 2018, claimed that the drugmakers impeded competitor access to Tracleer samples, effectively blocking the market entry of a competing generic product [1]. - Actelion Pharmaceuticals, which made billions from Tracleer sales, was acquired by Johnson & Johnson in 2017 [1]. - The plaintiffs include the Government Employees Health Association and other entities that reimbursed members for Tracleer usage [1].

Core Insights - Johnson & Johnson announced FDA approval for TECVAYLI® plus DARZALEX FASPRO® for treating relapsed/refractory multiple myeloma, potentially establishing a new standard of care as early as the second line of treatment [1][2] - The approval is based on Phase 3 MajesTEC-3 study data, showing significant improvements in progression-free survival (PFS) and overall survival (OS) compared to standard treatments [1][2] Company Overview - Johnson & Johnson is a leader in multiple myeloma therapies, emphasizing its commitment to transforming treatment landscapes for this disease [1][2] - The company has a history of innovation in hematology, aiming to improve patient outcomes and accessibility to effective therapies [1][2] Treatment Efficacy - TECVAYLI® in combination with DARZALEX FASPRO® demonstrated an 83% reduction in the risk of disease progression or death compared to standard regimens, with a three-year PFS rate of 83% versus 30% in the control arm [1][2] - The combination therapy showed higher rates of overall response (89% vs. 75.3%), complete response (81.8% vs. 32.1%), and minimal residual disease negativity (58.4% vs. 17.1%) at three years [1][2] Study Details - The MajesTEC-3 study is a randomized Phase 3 trial evaluating the safety and efficacy of teclistamab plus daratumumab against standard treatment options in patients with relapsed/refractory multiple myeloma [2] - The study's primary endpoint is PFS, with secondary endpoints including overall response rate, minimal residual disease negativity, and overall survival [2] Market Impact - The approval enhances treatment options for multiple myeloma patients, allowing for personalized treatment plans and potentially improving care accessibility [1][2] - Johnson & Johnson's new regimen is expected to address the critical need for effective therapies in patients experiencing multiple relapses [1][2] Future Aspirations - The company aims to continue advancing its multiple myeloma portfolio, with aspirations of ultimately curing the disease [1][2]

The U.S. Food and Drug Administration on Thursday approved Johnson & Johnson's treatment for a type of blood cancer, making it the third drug cleared under the agency's new speedy review prog... ...

Market Overview - The Dow Jones Index fell by 1055.18 points, a decrease of 2.16%, indicating a significant retreat for the blue-chip average [1] - Dow Futures also dropped by 1056.00 points, reflecting investor reactions to a surprising increase in the Consumer Price Index (CPI) [1] - The rise in CPI suggests potential delays in anticipated rate cuts by the Federal Reserve, leading to a broad-based sell-off across various sectors [1] - Market sentiment remains cautious as the yield on the 10-year Treasury increased, adding pressure on capital-intensive businesses [1] Sector Performance - The industrial and retail sectors experienced the most significant declines, with Caterpillar (CAT) down 4.67% due to concerns over higher interest rates affecting global construction spending [2] - Walmart (WMT) fell by 4.05% as rising costs threaten consumer income [2] - Financial companies struggled, with Goldman Sachs (GS) down 3.88% and American Express (AXP) down 1.67% [2] - Other notable decliners included Amgen (AMGN) down 3.99% and Home Depot (HD) down 2.27% [2] Notable Gainers - Salesforce (CRM) bucked the negative trend, rising by 4.36% driven by strong demand for AI [3] - IBM (IBM) increased by 2.82%, and Chevron (CVX) rose by 1.41% as energy prices provided a hedge against market volatility [3] - Microsoft (MSFT) also showed resilience, up by 0.75% [3] - However, these gains were overshadowed by losses in Johnson & Johnson (JNJ) down 3.73% and Honeywell (HON) down 3.70% [3]

Market Overview - U.S. equity markets are experiencing significant downward pressure due to escalating geopolitical tensions in the Middle East, impacting investor sentiment and energy prices [1][3] - The Dow Jones Industrial Average has dropped approximately 764 points, or 1.6%, trading near the 48,000 level, while the S&P 500 has retreated by 0.7% to 6,845 points, and the Nasdaq Composite is down only 0.3% [2] Geopolitical Impact - The ongoing conflict between U.S.-Israeli forces and Iran has triggered volatility, with Brent crude rising 3.8% to $84.52 per barrel and West Texas Intermediate (WTI) increasing nearly 6% to $79.07 [3] - Concerns over "energy-push" inflation are leading to sell-offs in price-sensitive sectors such as industrials and consumer discretionary [3] Economic Data - Domestic economic data shows a mixed but generally stable picture, with weekly initial jobless claims rising less than expected, indicating a tight labor market [4] - Fourth-quarter nonfarm productivity rose more than anticipated, suggesting potential efficiency gains to offset rising costs [4] Federal Reserve Outlook - The bond market is reacting to inflationary risks from higher oil prices, with the 10-year Treasury yield climbing to a three-week high of 4.15% [5] - Markets are pricing in a 97.3% likelihood that the Federal Reserve will keep interest rates unchanged at its upcoming March meeting [5] Corporate News - The technology sector is highlighted by Broadcom's stock jumping 6.6% after reporting first-quarter results that exceeded analyst estimates, driven by AI revenue more than doubling year-over-year [6] - Trade Desk's shares surged nearly 20% due to advanced talks with OpenAI for advertising solutions, while Veeva Systems rose over 5% after a positive fourth-quarter report and strong fiscal 2027 guidance [7] Retail and Consumer Sector - Kroger reported fourth-quarter earnings of $1.35 per share with identical sales growth of 2.4%, but shares traded flat due to rising logistics costs [8] - American Eagle Outfitters fell 4.5% after warning of potential tariff impacts reaching $60 million in the first half of the year [8] Notable Movers - Microsoft and Salesforce are among the few gainers in the Dow, while Merck, Johnson & Johnson, and Walmart are leading the index lower [9] - Nvidia and Amazon continue to attract high trading volume as key players in AI-driven momentum [9] Upcoming Events - Market participants are anticipating the release of the comprehensive February jobs report, which will be crucial for the Federal Reserve's future decisions in a complex global environment [10]

摩根大通将强生公司目标价从225美元上调至250美元。 本文源自：金融界AI电报 ...

Key TakeawaysWTI Crude jumped 2% at the market open as the Saudi Defense Ministry confirmed the interception of three cruise missiles near Al-Kharj, escalating fears of a broader regional war.Netflix (NFLX) officially abandoned its $110 billion pursuit of Warner Bros. Discovery (WBD) after being outbid by a $31-per-share offer from Paramount Skydance.Meta Platforms (META) announced plans to expand its in-house custom chip development for AI training to reduce its multi-billion dollar reliance on Nvidia (NVD ...

Core Insights - Johnson & Johnson has launched a direct-to-consumer website named J&J Direct to sell certain medications directly to U.S. patients without insurance or those paying out of pocket [1] - The website currently lists three drugs: diabetes treatments Invokana and Invokamet, and blood thinner Xarelto [1] - This initiative is part of a broader commitment by the company to enhance access to its drugs, following an agreement with the Trump administration aimed at reducing drug prices [1] Business - The company has pledged to invest $55 billion in the U.S. over four years as part of its strategy to improve drug accessibility [1] - Johnson & Johnson is among several pharmaceutical companies, including Pfizer and Eli Lilly, that have initiated direct-to-consumer sales platforms [1] - The U.S. government has also launched TrumpRx.gov, a website offering discounted prescription medicines, although Johnson & Johnson is not currently selling on this platform [1]

When markets get nervous, many investors do the same thing. They go to cash. But historically, periods of market fear often create some of the best trading opportunities — if you know where to look. More News from Barchart In a recent Market on Close segment, Barchart’s Senior Market Strategist John Rowland, CMT, explained how rising volatility can signal shifts in leadership across sectors — and how traders can identify opportunities even while broader sentiment turns cautious. The Signs of Fear Are A ...